Aliphatic Propargylamines as Treatments for Neurodegenerative Diseases

Catecholamine Research: From Molecular Insights to Clinical Medicine
  • Mark D. Berry
  • Alan A. Boulton
Part of the Advances in Behavioral Biology book series (ABBI, volume 53)

Abstract

During the past decade, apoptosis has been implicated increasingly as playing a role in a number of human neurodegenerative conditions. The acceptance of a role for apoptosis in human disease states has led to a marked increase in attempts to develop anti-apoptotic agents as potential therapeutics. We have developed a number of novel aliphatic compounds, several of which have been tested in a number of in vitro and in vivo model systems (Berry, 1999). Here we focus on data obtained from in vivo models of two neurodegenerative conditions, stroke and Parkinson’s disease.

Keywords

Lesion Volume Aliphatic Compound MPTP Administration MPTP Model Human Disease State 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bankiewicz, K. S., Oldfield, E. H., Chieuh, C. C., Doppman, J. L., Jacobwitz, D. M and Kopin, I. J., 1986, Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) Life Sci. 39:7–16PubMedCrossRefGoogle Scholar
  2. Berry, M. D. and Boulton, A. A., 2001, Aliphatic propargylamines as symptomatic and neuroprotective treatments for neurodegenerative diseases, Neurotoxicol. Teratol. (in press).Google Scholar
  3. Berry, M. D., 1999, R-2HMP: an orally active agent combining independent antiapoptotic and MAO-B-inhibitory activities, CNS Drug Rev. 5:105–124CrossRefGoogle Scholar
  4. Paterson, I. A., Barber, A. J., Gelowitz, D. L. and Voll, C., 1997, (-)Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells, Neurosci. Biobehav. Rev. 21:181–186PubMedCrossRefGoogle Scholar
  5. Yu, P. H., Davis, B. A. and Boulton, A. A., 1992, Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors, J. Med. Chem. 35:3705–3713PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Mark D. Berry
  • Alan A. Boulton
    • 1
  1. 1.ALviva Biopharmaceuticals Inc.SaskatoonCanada

Personalised recommendations